ArticleNature communications2024
Non-invasive transdermal delivery of biomacromolecules with fluorocarbon-modified chitosan for melanoma immunotherapy and viral vaccines.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeted-Penetrating Biomimetic Hybrid Transfersomes for Enhanced Transdermal Gene Transfection in Hypertrophic Scar Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Skin Relevant Biomaterials from Wound Healing, Medical Aesthetics, Flexible Electronics to Artificial Intelligence and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Machine Learning-Guided Near-Infrared Laser Processing for Precise Geometry Control in Microneedles with Downstream microLED-Triggered Photothermal Functionality.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Review
- Transdermal drug delivery systems in cancer therapy: advances, challenges, and future perspectives.European journal of clinical pharmacology · 2026Review
- Traditional Chinese medicine ingredients integrated microneedles: A promising strategy for transdermal treatment.Asian journal of pharmaceutical sciences · 2026Review
- Engineering spherical nucleic acids for precision cancer therapy: design strategies and medical applications.Theranostics · 2026Review
- Review
- Article
- Microneedle-Based Biofuel Cell with MXene/CNT Hybrid Bioanode: Fundamental and Biomedical Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Polymeric particle-based antigen delivery system: From immunological engineering to clinical translation.International journal of pharmaceutics: X · 2025Review
- Advances in cancer therapy using fluorinated chitosan: a promising nanoplatform for drug delivery.Medical oncology (Northwood, London, England) · 2025Review
- Bicelle-induced skin penetration mechanism for hydrophilic molecules.RSC advances · 2025Article
- Co-encapsulated Ce6 + CpG and biopeptide-modified liposomes for enhanced transdermal photo-immunotherapy of superficial tumors.Materials today. Bio · 2025Article
- Recent progress in topical and transdermal approaches for melanoma treatment.Drug delivery and translational research · 2025Review
- Therapeutic potential of natural polymer-based transdermal drug delivery system for musculoskeletal disorders.Biomaterials translational · 2025Article
- Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances.Journal of nanobiotechnology · 2024Review
- Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.Pharmaceutics · 2024Review
- Nanostructure-Mediated Transport of Therapeutics through Epithelial Barriers.International journal of molecular sciences · 2024Review
- Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Transdermal drug delivery has been regarded as an alternative to oral delivery and subcutaneous injection. However, needleless transdermal delivery of biomacromolecules remains a challenge. Herein, a transdermal delivery platform based on biocompatible fluorocarbon modified chitosan (FCS) is developed to achieve highly efficient non-invasive delivery of biomacromolecules including antibodies and antigens. The formed nanocomplexes exhibits effective transdermal penetration ability via both intercellular and transappendageal routes. Non-invasive transdermal delivery of immune checkpoint blockade antibodies induces stronger immune responses for melanoma in female mice and reduces systemic toxicity compared to intravenous injection. Moreover, transdermal delivery of a SARS-CoV-2 vaccine in female mice results in comparable humoral immunity as well as improved cellular immunity and immune memory compared to that achieved with subcutaneous vaccine injection. Additionally, FCS-based protein delivery systems demonstrate transdermal ability for rabbit and porcine skins. Thus, FCS-based transdermal delivery systems may provide a compelling opportunity to overcome the skin barrier for efficient transdermal delivery of bio-therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.